ANDREW MISCOVICH: Open Payments
NPI 1023786431 · SEATTLE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$788 in 39 payments from 8 companies in 2025. Trend: 2023 $140 · 2024 $636 · 2025 $788
Food & beverage: $788
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $330 |
| AstraZeneca Pharmaceuticals LP | 5 | $137 |
| Vanda Pharmaceuticals Inc. | 4 | $115 |
| Novo Nordisk Inc | 4 | $70 |
| Alexion Pharmaceuticals, Inc. | 2 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $39 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $36 |
| Exact Sciences Corporation | 1 | $18 |
Products named: VRAYLAR, AIRSUPRA, FANAPT, UBRELVY, Wegovy, JARDIANCE, JOURNAVX, PONVORY.
Industry payments across WA — which companies pay providers there.
